title: Sunitinib effective for rare thymus cancer.
abstract: In a phase II trial, the tyrosine kinase inhibitor sunitinib was effective in previously treated patients with thymic carcinoma, offering the first viable second-line treatment option for patients with this rare and aggressive form of thymus cancer.
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use*; D000077210:Sunitinib; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D000077210:Sunitinib